Spindle and giant cell carcinoma of the thyroid: A different therapeutic approach

Rogers, Joseph D.; Lindberg, Robert D.; Hill, C. Stratton; Gehan, Edmund A.

doi:10.1002/1097-0142(197410)34:4<1328::aid-cncr2820340446>3.0.co;2-#

Cited by 46 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a later study, Gottlieb & Stratton Hill (1974) noted a partial response in 2 patients out of 9, treated with adriamycin. Rogers et al (1974) have tried another modality combining surgery, radiotherapy and chemotherapy. In a combined program of methotrexate and radiotherapy Jereb et al (1975) gave intraarterial or systemic a low dose of methotrexate daily to five patients until toxic symptoms.…”

Section: Discussionmentioning

confidence: 99%

Combined Therapy for Undifferentiated Giant and Spindle Cell Carcinoma of the Thyroid

Andersson

Biörklund

Landberg

et al. 1977

Acta Oto-Laryngologica

View full text Add to dashboard Cite

Undifferentiated giant and spindle cell carcinoma is an unusual and high-grade malignant type of cancer of the thyroid. The results of surgical and/or radiotherapeutic treatment have been discouraging. Only a few patients respond to therapy, usually for a short time. Recently, a few reports have been published on the effect of chemotherapy or a combined treatment of surgery, radiotherapy and chemotherapy. In the present paper the results of combining radiotherapy and chemotherapy, 5-FU and cyclophosphamide, are reported. For the future a more aggressive approach is discussed. The therapy should include surgical resection of the main bulk of the tumour, followed by radiotherapy and concomitant chemotherapy and thereafter prolonged adjuvant chemotherapy. Acta Otolaryngol Downloaded from informahealthcare.com by Northwestern University on 12/27/14For personal use only.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined Therapy for Undifferentiated Giant and Spindle Cell Carcinoma of the Thyroid

Andersson

Biörklund

Landberg

et al. 1977

Acta Oto-Laryngologica

View full text Add to dashboard Cite

show abstract

“…The first successful report of local control of ATC by radiotherapy and concomitant chemotherapy (5-fluoruracil and cyclophosphamid) was in 1973 by Wallgren and Norin (26). A combination of dactinomycin and radiotherapy was in 1974 reported as successful in a small series (27). However, when this material was enlarged (1) and more advanced cases were included, no obvious beneficial effects were observed by this additional chemotherapy.…”

Section: Local Tumour Controlmentioning

confidence: 99%

Anaplastic Giant Cell Thyroid Carcinoma

2004

View full text Add to dashboard Cite

Anaplastic (giant cell) thyroid carcinoma (ATC), is one of the most aggressive malignancies in humans with a median survival time after diagnosis of 3-6 months. Death from ATC was earlier seen because of local growth and suffocation. ATC is uncommon, accounting for less than 5 % of all thyroid carcinomas. The diagnosis can be established by means of multiple fine needle aspiration biopsies, which are neither harmful nor troublesome for the patient. The cytological diagnosis of this high-grade malignant tumour is usually not difficult for a well trained cytologist. The intention to treat patients with ATC is cure, although only few of them survive. The majority of the patients are older than 60 years and treatment must be influenced by their high age. We have by using a combined modality regimen succeeded in achieving local control in most patients. Every effort should be made to control the primary tumour and thereby improve the quality of remaining life and it is important for patients, relatives and the personnel to know that cure is not impossible. Different treatment combinations have been used since 30 years including radiotherapy, cytostatic drugs and surgery, when feasible. In our latest combined regimen, 22 patients were treated with hyper fractionated radiotherapy 1.6Gy x 2 to a total target dose of 46 Gy given preoperatively, 20 mg doxorubicin was administered intravenously once weekly and surgery was carried out 2-3 weeks after the radiotherapy. 17 of these 22 patients were operated upon and none of these 17 patients got a local recurrence. In the future we are awaiting the development of new therapeutic approaches to this aggressive type of carcinoma. Inhibitors of angiogenesis might be useful. Combretastatin has displayed cytotoxicity against ATC cell lines and has had a positive effect on ATC in a patient. Sodium iodide symporter (NIS) genetherapy is also being currently considered for dedifferentiated thyroid carcinomas with the ultimate aim of making radio-iodine therapy possible.

show abstract

“…Μέχρι τό 1965 στά περισσότερα κέντρα ή εγχείρηση ήταν ή μόνη θεραπευτική προ σπάθεια καί μόνο άν ή εξαίρεση δέν ήταν ριζική άκολουθοΰσε εξωτερική ακτινοβο λία (Rogers, 1974-Aldinger, 1975.…”

Section: θεραπείαunclassified

“…Μετά τή διακοπή της θεραπείας ή νόσος υποτροπίασε σέ όλους τους ασθενείς. Στή θεραπεία τών γιγαντοκυττάρων καί άτρακτοκυτταρικών άμετάπλαστων όγ κων ό Rogers (1974) χρησιμοποίησε τήν Άκτινομυσιτίνη D σέ συνδυασμό μέ χειρουρ γική επέμβαση καί ακτινοθεραπεία καί φαίνεται νά πέτυχε μία μικρή παράταση της επιβίωσης. Ή άκτινομυσιτίνη D χορηγεϊτο σέ δόσεις 0,5 mg δύο φορές τήν εβδομά δα μέχρι τήν εμφάνιση τοξικών συμπτωμάτων.…”

Section: θεραπείαunclassified

“…Ή νόσος ετέθη ύπό έλεγχο σέ ενα μικρό αριθμό ασθε νών γιά δύο ή περισσότερα χρόνια. Ή μέση επιβίωση τών ασθενών πού έλαβαν τή θεραπεία ήταν 9 μήνες, ενώ ασθενείς πού είχαν υποστεί μόνο χειρουργική επέμβαση είχαν μία μέση επιβίωση δύο μηνών (Rogers, 1974).…”

Spindle and giant cell carcinoma of the thyroid: A different therapeutic approach

Cited by 46 publications

References 7 publications

Combined Therapy for Undifferentiated Giant and Spindle Cell Carcinoma of the Thyroid

Combined Therapy for Undifferentiated Giant and Spindle Cell Carcinoma of the Thyroid

Anaplastic Giant Cell Thyroid Carcinoma

Το Αμεταπλαστο Θυρεοειδικο Καρκινωμα

Contact Info

Product

Resources

About